Article and Video CATEGORIES

Cancer Journey

Search By

Can we predict which patients will benefit from Tarceva based on a blood test?
Wed, 06/12/2013 - 06:00
Author
GRACE Videos and Articles

Drs. Mary Pinder, Nate Pennell, and Jack West review results from the PROSE trial presented at ASCO 2013, testing the predictive value of the Veristrat test of serum proteomics to assess the potential value of erlotinib (Tarceva) in advanced NSCLC.

[powerpress]

Discuss this post in the GRACE Discussion Forums

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi szhang, I'm so sorry to know that your father is in this position.


It's not known if your father would have progressed in the same way whether he stayed on...

Hi Janine, thank you so much for your kind response. It definitely brought some clarity during this uncertain time for my father. He's scheduled for the first infusion next Tuesday with...

We're glad to help. The link in my previous post (at "2nd opinion". sorry I didn't even point it out) is a most excellent article to answer your questions so I...

Hi snickerdoodle, I'm sorry you're going through this worry. Cea levels for nsclc don't really inform treatment decisions. They sometimes forewarn the coming of progression but sometimes progression doesn't follow a...

I appreciate the comments. I also want to correct my mistake in CEA level- I forgot the decimal. In the past year, my level has increased from 4.7 to 28.3, NOT...

Hi Rick and welcome to Grace. I'm sorry you're going through this. Ethically or legally we can't comment on reports.
Cancer and infection look alike on film and they both cause...

Recent Comments

JOIN THE CONVERSATION
We're glad to help. The…
By JanineT Forum … on Wed, 06/29/2022 - 18:42
2nd Opinion and Update
By JanineT Forum … on Wed, 06/29/2022 - 15:26
Hi szhang, I'm so sorry to…
By JanineT Forum … on Wed, 06/29/2022 - 14:09
CEA 28.3
By snickerdoodle531 on Wed, 06/22/2022 - 16:05